Ultomiris (ravulizumab-cwvz) is a brand-name infusion prescribed for myasthenia gravis. This article covers topics such as side effects, dosage, and how Ultomiris works. Ultomiris is an ...

May 2, 2025 -- The FDA has approved a new treatment for generalized myasthenia gravis (gMG), a disease that causes severe muscle weakness, faster muscle fatigue, and difficulty in speaking and ...

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis. The Food and Drug Administration (FDA) has approved Imaavy ...

SAN DIEGO — Inebilizumab (Uplizna, Amgen) is safe and effective up to 52 weeks in patients with generalized myasthenia gravis (MG), new research suggested. If approved, the drug would ...

Antozzi C, Vu T, Ramchandren S, et al. Long-term safety and efficacy of nipocalimab in generalized myasthenia gravis: Vivacity-MG3 open-label extension phase results. Neurology. 2025;104(7 suppl 1 ...

MG-ADL scores improved, indicating enhanced daily functioning for patients with myasthenia gravis. Limitations include potential coding errors, selection biases, and missing clinical data ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years. The approval ...

Highlights in myasthenia gravis (MG) from the American Academy of Neurology 2025 Annual Meeting include new therapy trials and practice reviews, as discussed by Dr Nicholas Silvestri of the ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...